Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2023 Dec 21

PMID 38127827

Authors

Eylul Ozgu

Esranur Aydin

Ashkan Adibi

Unal Metin Tokat

Onur Tutar

Jiancheng Hu

Irem Demiray

Razelle Kurzrock

Mutlu Demiray

Affiliations

Soon will be listed here.

Citing Articles

Decoding the functional impact of the cancer genome through protein-protein interactions.

Fu H, Mo X, Ivanov A Nat Rev Cancer. 2025; 25(3):189-208.

PMID: 39810024 DOI: 10.1038/s41568-024-00784-6.

Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.

Ozgu E, Kaplan B, Sivakumar S, Sokol E, Aydin E, Tokat U BJC Rep. 2024; 2(1):77.

PMID: 39516363 PMC: 11524077. DOI: 10.1038/s44276-024-00086-2.

A rare presentation of primary cardiac myxofibrosarcoma: Case report and literature review.

Soltani S, Garousi M, Mirzaee E, Koolaji S, Nazari H, Emami S Cancer Rep (Hoboken). 2024; 7(4):e2033.

PMID: 38600050 PMC: 11006601. DOI: 10.1002/cnr2.2033.

References

Ogura K, Hosoda F, Arai Y, Nakamura H, Hama N, Totoki Y . Integrated genetic and epigenetic analysis of myxofibrosarcoma. Nat Commun. 2018; 9(1):2765. PMC: 6050269. DOI: 10.1038/s41467-018-03891-9. View

Pandit B, Sarkozy A, Pennacchio L, Carta C, Oishi K, Martinelli S . Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007; 39(8):1007-12. DOI: 10.1038/ng2073. View

Vanni S, De Vita A, Gurrieri L, Fausti V, Miserocchi G, Spadazzi C . Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol. 2022; 14:17588359221093973. PMC: 9244941. DOI: 10.1177/17588359221093973. View

Diamond E, Durham B, Ulaner G, Drill E, Buthorn J, Ki M . Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019; 567(7749):521-524. PMC: 6438729. DOI: 10.1038/s41586-019-1012-y. View

Pacaud A, Amintas S, Boussemart L, Cappellen D, Gerard E . A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy. Eur J Cancer. 2021; 147:161-163. DOI: 10.1016/j.ejca.2021.02.001. View

Subbiah V, Westin S, Wang K, Araujo D, Wang W, Miller V . Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol. 2014; 7:8. PMC: 3896681. DOI: 10.1186/1756-8722-7-8. View

Molzan M, Schumacher B, Ottmann C, Baljuls A, Polzien L, Weyand M . Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol. 2010; 30(19):4698-711. PMC: 2950525. DOI: 10.1128/MCB.01636-09. View

Kato S, Adashek J, Shaya J, Okamura R, Jimenez R, Lee S . Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. Clin Cancer Res. 2021; 27(10):2792-2797. PMC: 11005753. DOI: 10.1158/1078-0432.CCR-20-3761. View

Fan W, Wang C, Zhong X, Zheng Y, Chen T, Huang M . A Refractory Case of Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib. Onco Targets Ther. 2023; 16:23-29. PMC: 9869796. DOI: 10.2147/OTT.S390458. View

10.

Gao J, Aksoy B, Dogrusoz U, Dresdner G, Gross B, Sumer S . Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6(269):pl1. PMC: 4160307. DOI: 10.1126/scisignal.2004088. View

11.

Patterson S, Statz C, Yin T, Mockus S . Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data. NPJ Precis Oncol. 2019; 3:2. PMC: 6333807. DOI: 10.1038/s41698-018-0073-y. View

12.

McEvoy C, Xu H, Smith K, Etemadmoghadam D, Leong H, Choong D . Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. J Clin Invest. 2019; 129(5):1940-1945. PMC: 6486352. DOI: 10.1172/JCI123089. View

13.

Ahn E, Mangat P, Garrett-Mayer E, Halabi S, Dib E, Haggstrom D . Palbociclib in Patients With Non-Small-Cell Lung Cancer With Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2022; 4:757-766. DOI: 10.1200/PO.20.00037. View

14.

Elvin J, Gay L, Ort R, Shuluk J, Long J, Shelley L . Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common Alteration. Oncologist. 2017; 22(4):416-421. PMC: 5388371. DOI: 10.1634/theoncologist.2016-0310. View

15.

Blasco R, Francoz S, Santamaria D, Canamero M, Dubus P, Charron J . c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell. 2011; 19(5):652-63. PMC: 4854330. DOI: 10.1016/j.ccr.2011.04.002. View

16.

Zebisch A, Staber P, Delavar A, Bodner C, Hiden K, Fischereder K . Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 2006; 66(7):3401-8. DOI: 10.1158/0008-5472.CAN-05-0115. View

17.

Sicklick J, Kato S, Okamura R, Schwaederle M, Hahn M, Williams C . Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019; 25(5):744-750. PMC: 6553618. DOI: 10.1038/s41591-019-0407-5. View

18.

Rankin A, Johnson A, Roos A, Kannan G, Knipstein J, Britt N . Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers. Oncologist. 2020; 26(1):e153-e163. PMC: 7794197. DOI: 10.1002/ONCO.13519. View

19.

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View

20.

Kim K, Semrad T, Schrock A, Ali S, Ross J, Singer M . Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an Fusion. JCO Precis Oncol. 2022; 2:1-6. DOI: 10.1200/PO.17.00138. View